126 related articles for article (PubMed ID: 1389483)
21. [Intra-arterial infusion chemotherapy of advanced breast cancer--effects and side effects of adriamycin, 4'-epi-adriamycin and THP-adriamycin].
Toda K; Asaishi K; Okazaki M; Okazaki Y; Okazaki A; Sato H; Mikami T; Watanabe Y; Hayasaka H; Narimatsu E
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):3011-4. PubMed ID: 2782905
[TBL] [Abstract][Full Text] [Related]
22. Continuous infusion of low-dose doxorubicin, epirubicin and mitoxantrone in cancer chemotherapy: a review.
Greidanus J; Willemse PH; Uges DR; Oremus ET; De Langen ZJ; De Vries EG
Pharm Weekbl Sci; 1988 Dec; 10(6):237-45. PubMed ID: 3062572
[TBL] [Abstract][Full Text] [Related]
23. Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results.
Ventura GJ
J Clin Oncol; 2005 Apr; 23(12):2873; author reply 2873-4. PubMed ID: 15838014
[No Abstract] [Full Text] [Related]
24. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.
Cowan JD; Neidhart J; McClure S; Coltman CA; Gumbart C; Martino S; Hutchins LF; Stephens RL; Vaughan CB; Osborne CK
J Natl Cancer Inst; 1991 Aug; 83(15):1077-84. PubMed ID: 1875415
[TBL] [Abstract][Full Text] [Related]
25. Liposomal doxorubicin in breast cancer: new preparation. Much ado about nothing.
Prescrire Int; 2003 Jun; 12(65):93-5. PubMed ID: 12825572
[TBL] [Abstract][Full Text] [Related]
26. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue.
Cersosimo RJ; Hong WK
J Clin Oncol; 1986 Mar; 4(3):425-39. PubMed ID: 3005521
[TBL] [Abstract][Full Text] [Related]
27. Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group.
Findlay BP; Walker-Dilks C
Cancer Prev Control; 1998 Jun; 2(3):140-6. PubMed ID: 10093625
[TBL] [Abstract][Full Text] [Related]
28. Clinical comparison on the safety and efficacy of fluorouracil/pirarubicin/cyclophosphamide (FPC) with fluorouracil/ epirubicin/cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer.
Li Y; Tang JH; Huang XE; Li CG
Asian Pac J Cancer Prev; 2011; 12(7):1795-8. PubMed ID: 22126567
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of tetrahydropyranyl adriamycin (pirarubicin) in elderly patients with advanced breast cancer.
Chevallier B; Mignot L; Delozier T; Morvan F; Ferme C; Herait P
Am J Clin Oncol; 1992 Oct; 15(5):395-8. PubMed ID: 1524040
[TBL] [Abstract][Full Text] [Related]
30. Patient treatment preference in advanced breast cancer: a randomized cross-over study of doxorubicin and mitozantrone.
Stuart-Harris R; Simes RJ; Coates AS; Raghavan D; Devine R; Tattersall MH
Eur J Cancer Clin Oncol; 1987 May; 23(5):557-61. PubMed ID: 3653179
[TBL] [Abstract][Full Text] [Related]
31. Epirubicin. Clinical pharmacology and dose-effect relationship.
Robert J
Drugs; 1993; 45 Suppl 2():20-30. PubMed ID: 7693418
[TBL] [Abstract][Full Text] [Related]
32. Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer.
Ormrod D; Holm K; Goa K; Spencer C
Drugs Aging; 1999 Nov; 15(5):389-416. PubMed ID: 10600046
[TBL] [Abstract][Full Text] [Related]
33. Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.
Bontenbal M; Andersson M; Wildiers J; Cocconi G; Jassem J; Paridaens R; Rotmensz N; Sylvester R; Mouridsen HT; Klijn JG; van Oosterom AT
Br J Cancer; 1998 Jun; 77(12):2257-63. PubMed ID: 9649142
[TBL] [Abstract][Full Text] [Related]
34. An oriented phase II trial of THP-adriamycin in breast carcinoma.
Mathé G; Umezawa H; Oka S; Misset JL; Brienza S; de Vassal F; Musset M; Ribaud P; Tapiero H
Biomed Pharmacother; 1986; 40(10):376-9. PubMed ID: 3580506
[TBL] [Abstract][Full Text] [Related]
35. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
[TBL] [Abstract][Full Text] [Related]
36. Mitoxantrone: an active, new antitumor agent with an improved therapeutic index.
Saletan S
Cancer Treat Rev; 1987 Dec; 14(3-4):297-303. PubMed ID: 3326667
[No Abstract] [Full Text] [Related]
37. [Phase II study of epirubicin on breast cancer: a cooperative group study].
Tominaga T; Kitamura M; Nomura Y; Abe O; Enomoto K; Ikeda T; Izuo M; Iino Y; Taguchi T; Tamura K
Gan To Kagaku Ryoho; 1986 Jun; 13(6):2187-92. PubMed ID: 3459397
[TBL] [Abstract][Full Text] [Related]
38. Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study.
Lotrionte M; Palazzoni G; Abbate A; De Marco E; Mezzaroma E; Di Persio S; Frati G; Loperfido F; Biondi-Zoccai G
Int J Cardiol; 2013 Aug; 167(3):1055-7. PubMed ID: 23174173
[No Abstract] [Full Text] [Related]
39. Phase II study of doxorubicin versus epirubicin in advanced breast cancer.
Brambilla C; Rossi A; Bonfante V; Ferrari L; Villani F; Crippa F; Bonadonna G
Cancer Treat Rep; 1986 Feb; 70(2):261-6. PubMed ID: 3456271
[TBL] [Abstract][Full Text] [Related]
40. Copoly(styrene-maleic acid)-pirarubicin micelles: high tumor-targeting efficiency with little toxicity.
Greish K; Nagamitsu A; Fang J; Maeda H
Bioconjug Chem; 2005; 16(1):230-6. PubMed ID: 15656596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
